相关实验视频

Updated: Jun 12, 2025

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

对efanesoctocog alfa的药理动力学评估:对于血友病A的突破性XVIII因子疗法

Koji Yada¹, Keiji Nogami¹

¹Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan.

Expert opinion on drug metabolism & toxicology

|September 26, 2024

概括

一种新型重组因子VIII (FVIII) 的efanesoctocog alfa为血友病A治疗提供了延长的半衰期. 每周给药可提供持续的FVIII水平和有效的血液静止,解决患者未满足的需求.

科学领域:

血液学血液学血液学
药理学药理学是指药理学的学科.
生物技术是生物技术.

背景情况:

血友病A (HA) 是由第八因子 (FVIII) 缺乏引起的严重出血疾病.
目前的FVIII替代疗法需要频繁的剂量,给患有血友病A (PwHA) 的患者带来负担.
需要改进的FVIII疗法,具有更好的药理动力学特征.

研究的目的:

评估efanesoctocog alfa的疗效和安全性,这是一个新的重组FVIII.
评估efanesoctocog alfa的潜力,以克服血友病A治疗中的未满足需求.

主要方法:

Efanesoctocog alfa是一种B域删除的单链融合FVIII,使用特定的蛋白质成分进行工程.
它的设计允许独立于内源威尔布兰德因子 (VWF) 的功能.
第三阶段临床试验评估了其药理动力学特性和血静效应.

主要成果:

与现有的FVIII产品相比,Efanesoctocog alfa的半衰期比现有的FVIII产品长2至4倍.
每周一次的管理维持了整个星期的高FVIII活性水平.
在第三阶段临床试验中观察到出色的静血效应.

结论:

埃法尼索克托科格阿尔法表现出有前途的药理性质,并且耐受性良好.
它代表了PwHA在FVIII治疗中的重大进步.
进一步的长期安全性研究是有必要的,特别是在以前未经治疗的患者中.

关键词:

埃法尼索克托科格阿尔法 (Efanesoctocog alfa) 是一种可靠的药物.一个XTEN一个XTEN 延长半衰期延长半衰期第八个因子的因素.血友病A型血友病A型血友病A型

更多相关视频

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Time Course of Drug Effect

Time Course of Drug Effect

The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...